Questcor Pharma: (NASD: QCOR)

$37.34

0.48 (1.30%)

Volume 1,079,064

May 17 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		36.76 - 37.97
	
		52wk Low - High
		17.25 - 58.91
	
		Previous Close
		36.86
	
		Avg. Volume
		2,296,570
	
		Industry
		MED-DRUGS
	
		Market Cap
		2.19 B
	
		Div - Yield
		1.00 - 2.68
	
		Beta
		0.74
	
		PE (Forward)
		9.20
	
		Current Year Est.
		4.06
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		88 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/14/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            9.20
                        
                            PEG Ratio
                            0.41
                        
                            Current Year Est.
                            4.06
                        
                            Current Quarter Estimate
                            1.13
                        
                            Most Accurate Estimate
                            1.13
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-23-2013
                        
                            EPS Last Year
                            3.26
                        
                            Expected Earnings Growth
                            22.50%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Questcor Pharmaceuticals, Inc., formerly Cypros Pharmaceutical Corporation, is an integrated specialty pharmaceutical company focused on the development, acquisition and marketing of innovative, acute care and critical care hospital/specialty pharmaceutical products.   
Full QCOR Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
QCOR Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	1.13	1.12	4.06	4.01
Number of Estimates	1	1	1	1
Low Estimate	1.13	1.12	4.06	4.01
High Estimate	1.13	1.12	4.06	NA
Year Ago EPS	0.65	0.92	3.15	4.06
EPS Growth	73.85%	21.74%	28.89%	-1.23%

More QCOR Estimates

Average Earnings Estimates for QCOR

EPS Growth for QCOR

Industry Analysis

Name	Symbol	Previous Close
QUESTCOR PHARMA	QCOR	37.34
JAZZ PHARMACEUT	JAZZ	58.36
SALIX PHARM-LTD	SLXP	59.28
SANTARUS INC	SNTS	21.91
USANA HLTH SCI	USNA	65.46
BIOCRYST PHARMA	BCRX	1.71
CATALYST PHARMA	CPRX	0.83
CELL THERAPEUT	CTIC	1.16
CUBIST PHARM	CBST	49.51
ELAN CP PLC ADR	ELN	11.67

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Questcor Misses on Earnings, Revs

May 03, 2013

Questcor Beats Overall

Feb 27, 2013

Is the Correction Over, or Just Getting Started?

Feb 26, 2013

Questcor Acquires BioVectra

Jan 22, 2013

Questcor Set to Acquire BioVectra

Jan 04, 2013

Company News for December 28, 2012

Dec 28, 2012

ARIAD Announced Ponatinib Data

Dec 17, 2012

Gilead to Buy YM BioSciences

Dec 13, 2012

More QCOR Zacks Commentary

Financials

EPS TTM	3.26
Sales	509
Net Income	198
Price/Earnings	11.45
Price/Book	11.17
Price/Cash Flow	10.81
Price/Sales	3.99

More QCOR Financials

News

Questcor Pharmaceuticals Earnings Review: 18 Days after Announcement Shares Up 21.5% (QCOR) - Financial News Network Online - Earnings Lookback

May 18, 2013

3 Value Investing Plays in Health Care - TheMotleyFool

May 16, 2013

Critical Alerts For SanDisk, Computer Sciences, American Tower Corp, Questcor Pharmaceuticals, and Regeneron Pharmaceuticals Released By InvestorsObserver - Pr Newswire

May 15, 2013

Market Wrap for Wednesday, May 15: Bull Market Continues as Dow and S&P Hit New Highs - Benzinga

May 15, 2013

Mid-Afternoon Market Update: Computer Science Corporation Falls as Markets - Benzinga

May 15, 2013

Buyers Accumulate Shares of Questcor Pharmaceuticals, Up 3.8% - Financial News Network Online - Market Movers

May 14, 2013

Buyers Accumulating Shares of Questcor Pharmaceuticals on 1.5x Above-Average Volume (QCOR) - Financial News Network Online - Unusual Volume

May 14, 2013

Market Wrap for Tuesday, May 14: Stocks Rally to New Highs - Benzinga

May 14, 2013

See All News Stories on QCOR

Broker Recommendations

Current ABR	1.50
ABR (Last Week)	1.50
# of recs in ABR	8
Average Target Price	48.00
Industry Rank by ABR	88 out of 265
Rank in Industry	17 out of 91

More QCOR Broker Recommendations

Day Low - High	36.76 - 37.97
52wk Low - High	17.25 - 58.91
Previous Close	36.86
Avg. Volume	2,296,570
Industry	MED-DRUGS
Market Cap	2.19 B
Div - Yield	1.00 - 2.68
Beta	0.74
PE (Forward)	9.20
Current Year Est.	4.06
Quarterly Earnings ESP	0.00%

PE (Forward)	9.20
PEG Ratio	0.41
Current Year Est.	4.06
Current Quarter Estimate	1.13
Most Accurate Estimate	1.13
Earnings ESP	0.00%
Next Earnings Report Date	07-23-2013
EPS Last Year	3.26
Expected Earnings Growth	22.50%

Username: Password:

Remember me [?]

Questcor Pharma: (NASD: QCOR)

$37.34

0.48 (1.30%)

Volume 1,079,064

May 17 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations